Hypertensive (SHR) and nonhypertensive [Wistar-Kyoto (WKY); Sprague-Dawley (SD)] strains of rats received the dipeptide sweetener aspartame (200 mg/kg) or, as a positive control, tyrosine (200 mg/kg) by gavage or parenterally, after a brief (2-h) fast. Two hours later, compared with those of saline controls brain levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylethylethyleneglycol (MHPG) sulfate were significantly higher in the hypothalamus (WKY), locus coeruleus (SD and SHR) and brain stem (SHR) in tyrosine-treated animals, and in the locus coeruleus (SD) of those given aspartame. Brain norepinephrine levels were also higher, compared with those of saline-treated control rats, in the cerebral cortex (SD and SHR), amygdala (SD) and locus coeruleus (WKY) after tyrosine administration, and in the amygdala (SD) and cerebral cortex (SHR) after aspartame administration. In another study, oral aspartame was found to be at least as effective as the parenteral ly administered sweetener in raising regional brain levels of tyrosine or MHPG sulfate (i.e., compared with corresponding levels in saline-treated rats). Animals receiving oral aspartame also exhibited higher plasma tyrosine and phenylalanine ratios (i.e., the ratios of their plasma concentrations to the summed concentrations of other large neutral amino acids that compete with them for uptake into the brain), than animals receiving saline.
INDEXING
KEY WORDS â€¢ MHPG sulfate â€¢sweetener aspartame â€¢tyrosine hypertension â€¢ rat catecholamine Administration of the dipeptide sweet ener aspartame (L-aspartylphenyalanylmethyl ester) can elevate brain levels of phenylalanine and, especially, tyrosine in the rat (1) (2) (3) . Moreover, aspartame, like exogenous tyrosine (4), can lower blood pressure in spontaneously hypertensive (SHR) strains (5) . Since the mechanism of tyrosine's antihypertensive action in SHR in volves enhancing norepinephrine (NE) syn thesis in and release from, certain brain neurons (6, 7), we have inquired as to whether oral or parenteral aspartame (or parenteral tyrosine, a positive control) also affect the release of brain catecholamines.
For these studies we have used both SHR and two nonhypertensive strains [WistarKyoto (WKY) and Sprague-Dawley (SD) rats) and have inferred distribution of brain NE release from regional levels of MHPG sulfate, an NE metabolite thought to pro vide an index of brain NE release (8) . Our studies affirm that the sweetener has only minor effects on brain levels of the catecholamines [dopamine (DA); NE; epinephrine (E)] (3); that its ability to raise brain MHPG sulfate levels is at least as great after oral as after parenteral administration; and that its ability to elevate the plasma amino acid ratios that control brain tyrosine or phenylalanine levels (9, 10) does not require that animals be subjected to an overnight fast (1, 2) .
MATERIALS AND METHODS
Adult male SD, WKY, and SHR rats (Charles River Breeding Laboratories, Wil mington, MA) weighing about 250 g (expt 1), and SD rats weighing 200 g (expt 2) or 130 g (expt 3) were housed in individual cages in our animal facility for 7 d and given ad libitum access to diet (Charles River Rat, Mouse and Hamster Maintenance Formula; 26.5% protein) and tap water. The room temperature was maintained at 22 Â°C, and animals were exposed to light (Vita-lite; Duro-Test Corp., North Bergen, NJ) be tween 0700 and 1900 h daily.
On the day of an experiment, animals were deprived of food at 0700 h. Two hours later, at 0900 h, they received l ml/100 g of normal saline, aspartame (Ajinomoto Co., Inc., New York, NY) or tyrosine (given as a positive control), as slurries in the saline. In experiment 1, animals received tyrosine (200 mg/kg), aspartame (200 mg/kg), or saline, all intraperitoneally; in experiment 2, they received aspartame (200 mg/kg) or saline, intraperitoneally or by gavage; in experi ment 3, rats received aspartame (300 mg/kg) or saline, orally. (The aspartame was given by injection in some of the studiesâ€"even though this food additive enters humans via the oral route, as part of the dietâ€"because the SHR are very temperamental and diffi cult to handle: it was easier to administer the sweetener by injection. However, as demonstrated below, its effects on brain tyrosine when given orally were found to be at least as great as when given i.p..) After an additional 2 h, rats were decapitated, and their brains were immediately removed, frozen on dry ice, and stored at â€" 70 Â°C until assayed. Blood was collected from the cer vical wound, and plasma samples were stored at -20Â°C until assayed.
Brain dissection. Brain samples were taken from six norepinephrine-containing brain regions: hypothalamus, cerebral cortex, hippocampus, amygdala, locus coeruleus and brain stem. Hypothalamus, hippocam pus and cortex were dissected as described by Reinstein et al. (11) , with cortex in cluding the frontal, cingulate and parietal regions. The amygdala was dissected by making coronal cuts at the anterior border of the thalamus and just posterior to the mamillary bodies. A block of tissue from the temporal aspect of the cortex, containing the nuclei of the amygdaloid complex, was removed bilaterally. To dissect the locus coeruleus a coronal section was made just anterior to the pontine region and another just posterior to the obex region on the floor of the fourth ventricle. A portion of the resulting tissue including the middle third along the sagittal plane and top third along the horizontal plane was dissected; this contained the locus coeruleus. The remain ing tissue comprising the pontine region and medulla was taken as brain stem.
Neurochemical analysis. Brain regions were homogenized in 0.1 N perchloric acid and analyzed for tyrosine (12) , NE, E, DA, 3, 4-dihydroxyphenylacetic acid (DOPAC) and MHPG sulfate (13, 14) . The catecholamines NE, E, DA and DOPAC were puri fied over alumina and then assayed by using low polarity, reverse-phase high perfor mance liquid chromatography (HPLC) with electrochemical detection (13) (14) (15) . Separa tions were achieved using a Bondapak C\s column (Waters Associates, Milford, MA). The mobile phase consisted of 0.07 M sodi um phosphate, 0.1 mM EDTA and 0.35 mM sodium octyl-sulfate adjusted to a pH of 4.3, and 4% methanol; dihydroxybenzylamine served as an internal standard. The glassy carbon electrode was set at a potential of + 0.75 V against the Ag/AgCl reference electrode MHPG sulfate was first hydrolyzed enzymatically to MHPG; this was then extracted into ethyl acetate, backextracted into a 0.05 M sodium phosphate buffer and assayed by using the HPLC sys tem described above Amino acid concentra tions in plasma were assayed by HPLC (16) .
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Brain tyrosine was measured fluorimetrically (12) .
Statistical analysis. The statistical sig nificance of differences between values was determined by analysis of variance and Duncan's multiple range test (17) . In experi ment 2, the overall statistical significance of differences between values was determined by three-factor analyses of variance with repeated measures across brain regions. Post hoc ScheffÃ© tests (18) for differences among regions, and Dunnett tests (17) for differ ences between treatments, were then applied.
RESULTS

Effect of asportarne on tyrosine, catecholamine and MHPG sulfate levels in brain regions of various rat strains (ex.pt 1)
. Tyro sine concentrations in the hypothalamus, hippocampus and amygdala of all three strains examined and in the cerebral cortex and locus coeruleus of some of the strains were significantly higher in rats after parenteral tyrosine administration than after saline administration; in most regions, they were also higher than after aspartame ad ministration (table 1) . Tyrosine concentra tions in the hypothalamus, amygdala and locus coeruleus of SHR were higher after aspartame than after saline, but no sig nificant changes in brain tyrosine were observedâ€"in the one dose and after the single time intervals studiedâ€"in the SD and WKY rats. As described previously (3), tyrosine or aspartame had only minor effects on region al brain levels of NE or DA. NE levels were significantly higher after tyrosine than after saline injection in the cerebral cortex of SD and SHR rats, in the amygdala of SD rats and in the locus coeruleus of WKY; NE con centrations in the cerebral cortex of SHR and the amygdala of SD animals were higher after aspartame than after saline injection (table 2) . Tyrosine and aspartame paradoxically each lowered hippocampal NE in one strain (WKY and SHR, respec tively) compared with the concentrations observed in saline-treated controls. Tyrosine 'Rats (250 g) received 1 ml/100 g of saline, or of a saline slurry containing aspartame (200 mg/kg) or tyrosine (200 mg/kg) i.p. at 0900 h, 2 h after food had been removed, and were killed 2 h later. Rat strains used were Sprague-Dawley (SD), Wistar-Kyoto (WKY), and spontaneously hypertensive (SHR). Data are means Â±SEMof six rats per group. 2Means within a column not followed by the same letter are significantly different (P < 0.05).
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,co-*>r>int~-*cp X â€¢a V SA, or aspartame also lowered E levels in the amygdala of SHR, and tyrosine lowered E levels in the amygdala of WKY compared to saline-treated controls (table 3) . Aspartame raises E levels in the amygdala* of SD rats, compared with those seen in animals re ceiving saline Regional brain NE levels tended in general to be higher in SHR than in the other two strains, especially in the cerebral cortex, hippocampus and amygdala (table 2) .
Levels of DA (table 4) and its metabolite DOPAC (table 3) in the hypothalamus of SD rats, of DA in the cerebral cortex of SD rats, and of DA in the hypothalamus, cerebral cortex and locus coeruleus of WKY animals were higher in rats given tyrosine than in those given saline Tyrosine administration had no effect on DA levels in any brain region of SHR (table 4), but DOPAC levels were lowered in the hypothalamus of these animals. Aspartame raised DOPAC levels in the hypothalamus and amygdala of SD rats compared with those seen in saline-treated animals (table 3) but lowered them in SHR.
MHPG sulfate levels in the hypothalamus (WKY), cerebral cortex (WKY), locus coeru leus (SD), and brain stem (SHR) were higher in rats administered tyrosine than in those receiving saline; levels in the locus coeruleus (SD) were higher in rats adminis tered aspartame than in those receiving saline (table 5) .
Effect of oral versus i.p. aspartame on brain tyrosine and MHPG sulfate levels in SD rats (expt 2). We compared the changes in regional brain tyrosine or MHPG sulfate levels produced by giving saline orally or intraperitoneally, with those produced by giving aspartame by these routes (table 6). Oral aspartame was at least as effective as the parenteral sweetener in raising tyrosine levels within the hypothalamus, cerebral cortex, hippocampus, locus coeruleus and brain stem. Oral aspartame was also at least as effective as parenteral aspartame in rais ing MHPG sulfate levels in the amygdala and brain stem.
Effect of oral aspartame on plasma amino acid concentrations and ratios in nonfasted SD rats (expt 3). Our previous studies on
aspartame's effects on plasma and brain amino acids were with rats fasted overnight (2). To determine whether changes would also occur with the doses used here if the sweetener werre given to nonfasted animals, we examined blood amino acid levels and ratios in rats given the sweetener after being without food for only 2 h. As noted previ ously, plasma tyrosine and phenylalanine 2Means within a column not followed by the same letter are significantly different (P < 0.05).
levels, and the plasma phenylalanine ratios [i.e, the ratios of their plasma concentra tions to the summed concentrations of the five other large neutral amino acids (table 7) that most effectively compete with them for brain uptake (2, 9)], were higher in rats given aspartame orally, without fasting, than in saline controls. And as noted previ ously (2), the changes in phenylalanine levels and ratios were both proportionately and absolutely smaller than those in tyro sine levels and ratios. Plasma ratios of the 'Animals were prepared as described in table 1, footnote 1. Amygdala samples were unavailable, having been used for assays of epinephrine and DOPAC (table 4). Data are means Â±SEMof six rats per group. 2Means within a column not followed by the same letter are significantly different (P < 0.05).
TABLES
Effects of intraperitoneally administered aspartame or tyrosine on 3-methoxy-4-hydroxyphenylethylethelyneglycol-sulfate (MHPG-SO4) concentrations in brain regions
by guest on July 9, 2011 jn.nutrition.org Downloaded from 'SD rats (200 g) received 1 ml/100 g of saline, or of a saline slurry containing aspartame (200 mg/kg) i.p. or by gavage 0900 h, 2 h after food had been removed, and were killed 2 h later. Data given are means Â±SEM of six rats per group.
'In each row, means within a column not sharing a common letter differ (detailed in the materials and methods section) (P < 0.05).
'Overall differences between saline-and aspartame-treated groups, for tyrosine and MHPG-SO4 concentrations, were significant (P < 0.05) by Dennett's test.
other large neutral amino acids were lower in rats given aspartame than in those given saline (table 7) . DISCUSSION These data show that, depending on the strain studied, doses of aspartame that can raise brain tyrosine levels (table 1) are also able to affect the release of brain NE as reflected by elevated levels of the NE metab olite MHPG sulfate within the rat's locus coeruleus (table 5) or its amygdala and brain stem (table 6 ). The data also demon strate that giving the sweetener orally is at least as effective in this regard as giving it parenterally (table 6); and that aspartame's ability to affect the plasma tyrosine ratio (table 7) or, for that matter, brain levels of tyrosine, the catecholamines or such catecholamine metabolites as MHPG sulfate or DOPAC (tables 1-3, 5, 6) does not require that test animals have first been subjected to a prolonged overnight fast prior to its administration. The findings are compatible with the hypothesis (5) that the mechanism through which aspartame, like tyrosine (4), lowers blood pressure in SHR involves the sequential elevations that the sweetener produces in the plasma tyrosine ratio (2), brain tyrosine levels (2, 4) , and the release of NE from catecholaminergic brain neurons including those in the locus coeruleus (4, 6) .
The doses of aspartame that we used to produce these effects (200 or 300 mg/kg) are high, probably corresponding to 40-50 mg/kg for a human [or 20-25 mg/kg if it is consumed along with a protein-free, carbo hydrate-rich snack that lowers plasma levels of other large, neutral amino acids (1, 2,) ]. The phenylalanine content of the 200 mg/kg dose is 112 mg/kg, or 0.68 mmol/kg; even if all of this amino acid were immediately converted to tyrosine, and then metabolized exactly like exogenous tyrosine, it would still provide only about 62% as much tyrosine (123 mg/kg or 0.68 mmol/kg) as the amount we gave to our positive-control animals. Hence, it is not surprising that greater changes in brain catecholamine metabolism were seen in the animals receiving tyrosine than in those given aspartame Both tyrosine and aspartame administra tion caused reductions in NE (table 2) or E (table 3) levels within one or more brain regions, even though, in general, tyrosine levels in these regions were concurrently increased. We are unable to explain these reductions, which probably reflect transsynaptic consequences of the increases in tyrosine For example, if giving aspartame or tyrosine enhances the release of dopamine or norepinephrine into synapses where this transmitter is inhibitory, and if the postsynaptic cells subjected to this inhibition happen also to be catecholaminergic, then tyrosine could, by stimulating NE release within one brain region, diminish catecholamine release elsewhere We failed to detect any consistent differences between the hy pertensive and normotensive rat strains in the responses of their brain catecholamines to aspartame or tyrosine The significance of our findings in pre dicting aspartame's effects on humans is unclear. The human liver converts phenylalanine to tyrosine much less rapidly than does the rat liver, hence the major effect of high aspartame intake is to elevate the plasma phenylalanine ratio (19) and thereby brain phenylalanine, instead of tyrosine Phenylalanine has been described as both a substrate (Kaufman, S., personal communi cation) and an inhibitor (20, 21) of tyrosine hydroxylase, the enzyme that catalyzes the rate-limiting step in converting tyrosine to catecholamines. Moreover, we are unaware of any data on the effects of high phenyl alanine concentrations on the actual synthe sis and release of brain catecholamines, when provided (as would be the case) in the presence of physiological tyrosine concentra tions. Further studies with brain slices exposed to tyrosine and phenylalanine in concentrations like those occurring within human brain after aspartame consumption (i.e, as estimated from the plasma phenyl alanine and tyrosine ratios) will be neces sary to determine whether the sweetener is likely to increase or decrease brain catecholamine synthesis in brains of people
